



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 July 2016
EMA/HMPC/436679/2015
Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Althaea officinalis* L., radix

Final

Discussion in Working Party on European Union monographs and list (MLWP)	March 2008 May 2008 July 2008
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	17 July 2008
End of consultation (deadline for comments)	15 November 2008
Re-discussion in MLWP	January 2009 March 2009
Adoption by HMPC Monograph (EMA/HMPC/98717/2008) AR (EMA/HMPC/98718/2008) List of references (EMA/HMPC/98716/2008) Overview of comments received during the public consultation (EMA/HMPC/2920/2009) HMPC Opinion (EMA/HMPC/109223/2009)	14 May 2009
First systematic review	
Discussion in MLWP	July 2015 September 2015
Adoption by HMPC	24 November 2015
End of consultation (deadline for comments)	15 March 2016
Re-discussion in MLWP	May/June 2016
Adoption by HMPC	12 July 2016

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; traditional use; <i>Althaea officinalis</i> L., radix; Althaeae radix; marshmallow root
----------	--



BG (bulgarski): Лечебна ружа, корен	LT (lietuvių kalba): Svilarožių šaknys
CS (čeština): proskurníkový kořen	LV (latviešu valoda): Altejas saknes
DA (dansk): Altæarod	MT (Malti): Għerq tal-Ħobbejża Mediċinali
DE (Deutsch): Eibischwurzel	NL (Nederlands): Echte Heemst
EL (elliniká): ρίζα αλταίας-ρίζα αλθαίας	PL (polski): Korzeń prawoślazu
EN (English): marshmallow root	PT (português): Alteia, raiz
ES (español): Altea, raíz de	RO (română): rădăcină de nalbă mare
ET (eesti keel): alteejuur	SK (slovenčina): Koreň ibiša
FI (suomi): rohtosalkoruu, juuri	SL (slovenščina): korenina navadnega sleza
FR (français): Guimauve (racine de)	SV (svenska): Läkemalva, rot
HR (hrvatski): korijen običnog bijelog sljeza	IS (íslenska):
HU (magyar): orvosi ziliz gyökér	NO (norsk): Altearot
IT (italiano): Altea radice	

European Union herbal monograph on *Althaea officinalis* L., radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended <i>Althaea officinalis</i> L., radix (marshmallow root) i) Herbal substance Not applicable ii) Herbal preparations a) Comminuted herbal substance b) Liquid extract (DER 1:19.5-23.5), extraction solvent water c) Macerate for preparation of syrup³ d) Dry extract (DER 3-9:1), extraction solvent water⁴ e) Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V)

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use. Comminuted herbal substance for macerate preparation for oromucosal use. Herbal preparations in liquid or solid dosage forms for oral or oromucosal use.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

² The material complies with the Ph. Eur. monograph (ref.: 1126).

³ Prepared in accordance with the pharmacopoeial monographs for Sirupus althaeae in Österreichisches Arzneibuch 1981, Československý lékopis 1954, Farmakopea Polska 1970 and 2002 or with the monograph Eibischsirup in Deutscher Arzneimittel-Codex 1979.

⁴ A narrow range of the DER should be specified for each product.

Well-established use	Traditional use
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1) Traditional herbal medicinal product used as a demulcent preparation for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough. Indication 2) Traditional herbal medicinal product used as a demulcent preparation for the symptomatic relief of mild gastrointestinal discomfort. The product is a traditional herbal medicinal product for use in the specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration⁵

Well-established use	Traditional use
	Posology a) Comminuted herbal substance Indication 1) <i>Children 3-5 years of age</i> 0.5–1.0 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Daily dose: 1.5–3.0 g <i>Children 6-11 years of age</i> 0.5–1.5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Daily dose: 1.5–4.5 g <i>Adolescents, adults and elderly</i> 0.5-3 g of the comminuted herbal substance in

⁵ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	150 ml of water as a macerate several times daily Maximum daily dose: 15 g The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Indication 2) <i>Adolescents, adults and elderly</i> Herbal tea: 2-5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Maximum daily dose: 15 g The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). b) Liquid extract (DER 1:19.5-23.5) Indication 1) <i>Children 3-5 years of age</i> Single dose: 1.9 g 4 times daily Daily dose: 7.6 g <i>Children 6-11 years of age</i> Single dose: 2.3 g 5 times daily Daily dose: 11.5 g <i>Adolescents, adults and elderly</i> Single dose: 4.6 g 3–6 times daily Daily dose: 13.8–27.6 g The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). c) Macerate for preparation of syrup Indication 1) <i>Children 3-5 years of age</i> Single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) up to 4 times daily

Well-established use	Traditional use
	Daily dose: macerate amount corresponding to 0.21 to 1.16 g of herbal substance (10–20 ml of syrup) <i>Children 6-11 years of age</i> Single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) 3-5 times daily Daily dose: macerate amount corresponding to 0.32 to 1.45 g of the herbal substance (15–25 ml of syrup) <i>Adolescents, adults and elderly</i> Single dose: macerate amount corresponding to 0.21 to 0.87 g of the herbal substance (10–15 ml of syrup) 3–5 times daily Daily dose: macerate amount corresponding to 0.63 to 2.9 g of the herbal substance (30–50 ml of syrup) The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). d) Dry extract (DER 3-9:1) Indication 1) <i>Children 3-5 years of age</i> Single dose: extract amount corresponding to 0.5–1 g of herbal substance, 3 times daily Daily dose: extract amount corresponding to 1.5–3 g of herbal substance <i>Children 6-11 years of age</i> Single dose: extract amount corresponding to 0.5–1.5 g of herbal substance, 3 times daily Daily dose: extract amount corresponding to 1.5–4.5 g of herbal substance <i>Adolescents, adults and elderly</i> Single dose: extract amount corresponding to 0.5–3 g of herbal substance, several times daily Maximum daily dose: extract amount corresponding to 15 g of herbal substance

Well-established use	Traditional use
	The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). The use of solid dosage forms in children under 6 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). e) Liquid extract (DER 1:1) Indication 1) and 2) <i>Adults and elderly</i> Single dose: 2–5 ml 3 times daily Daily dose: 6–15 ml The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Duration of use Indication 1) If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Indication 1) Oral or oromucosal use Indication 2) Oral use The macerate should be used immediately after preparation.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indication 1) If dyspnoea, fever or purulent sputum occurs during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. <i>Preparations a), b), c) and d)</i> The use in children under 3 years of age is not recommended because of concerns requiring medical advice. The use of the solid dosage form in children under 6 years of age is not recommended because of the pharmaceutical form. <i>Preparation e)</i> The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. Indication 2) <i>Preparation a)</i> The use in children under 12 years of age has not been established due to lack of adequate data. <i>Preparation e)</i> The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. Indications 1) and 2) Absorption of concomitantly administered medicines may be delayed. As a precautionary measure, the product should not be taken ½ to 1 hour before or after intake of other medicinal products. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be

Well-established use	Traditional use
	included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of

Well-established use	Traditional use
	Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on genotoxicity have not been performed. Tests on reproductive toxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable

7. Date of compilation / last revision

12 July 2016